Article Text

Download PDFPDF
Reversible myelofibrosis secondary to systemic lupus erythematosus
  1. Murali Mohan Rama Krishna Reddy1,
  2. Archith Boloor1 and
  3. Nikhil Kenny Thomas2
  1. 1Department of Medicine, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, Mangalore, Karnataka, India
  2. 2Gastroenterology and Hepatology, St Luke's Hospital, Pathanamthitta, Kerala, India
  1. Correspondence to Dr. Archith Boloor; archith.boloor{at}manipal.edu

Abstract

Pancytopenia due to systemic lupus erythematosus (SLE) is rarely reported, and among those reported, it is mostly due to immunologically mediated cell destruction. Pancytopenia due to bone marrow fibrosis secondary to SLE is an extremely rare entity. Myelofibrosis secondary to SLE per se is reported only in 21 cases in the literature. Ours probably is the 22nd case report on SLE with myelofibrosis. Primary presentation of SLE with bleeding manifestation is also a rare phenomenon. Partial to complete regression of myelofibrosis is noted following treatment in secondary myelofibrosis caused by SLE. We report a case of a woman in her late 40s who presented to us with bleeding manifestations of petechial rash and menorrhagia, which on further evaluation showed pancytopenia due to myelofibrosis secondary to SLE. Our case underlines multiple features like primary bleeding manifestation and regression of myelofibrosis following treatment which is rarely reported in association with SLE.

  • Haematology (incl blood transfusion)
  • Systemic lupus erythematosus

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigations results and critical revision for important intellectual content: RKRM, BA and TNK. The following authors gave final approval of the manuscript: RKRM, BA and TNK.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.